Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 9 pages
Data source: Published sources
Share a link:
https://casecent.re/p/19876
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
After Aventis rejected the hostile takeover bid of Sanofi-Synthelabo on the grounds of financial inadequacy in January 2004, it approached Novartis, the Swiss drug manufacturer, to acquire it and save it from the potential acquisition. Although the Novartis-Aventis combination had the potential to form the second largest pharmaceutical company in the world with combined revenues of $47 billion, the French government was against the takeover of Aventis by a foreign company. This case highlights the probable synergies in case Aventis is acquired by Novartis.
About
Abstract
After Aventis rejected the hostile takeover bid of Sanofi-Synthelabo on the grounds of financial inadequacy in January 2004, it approached Novartis, the Swiss drug manufacturer, to acquire it and save it from the potential acquisition. Although the Novartis-Aventis combination had the potential to form the second largest pharmaceutical company in the world with combined revenues of $47 billion, the French government was against the takeover of Aventis by a foreign company. This case highlights the probable synergies in case Aventis is acquired by Novartis.